57th ASH Annual Meeting and Exposition (December 5-8, 2015): 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Poster III

Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

Identification of a New AHI-1-Mediated-PP2A-Beta-Catenin-BCR-ABL-JAK2 Complex Modulating Resistance of CML Stem/Progenitor Cells to Tyrosine Kinase Inhibitors

Damian Lai, BSc^1,2^*, Xiaohu Liu, MSc^1,2, Min Chen, PhD²^*, Katharina Rothe, BSc, MSc^2,3 and Jiang Xiaoyan, MD, PhD^1,2,3^*

¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada
²Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada
³Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

4013

Aryl Hydrocarbon Receptor (AhR) Pathway Directly Controls Hematopoietic Proliferation in Chronic Myeloid Leukemia (CML) and Its Inhibition Allows Massive Expansion of Leukemic Progenitors and Stem Cells

Melanie Gentil, MD¹^*, Patricia Hugues²^*, Gladys Telliam²^*, Ivan Sloma, PharmD, PhD³^*, Seda Baykal⁴^*, Jerome Artus, PhD²^*, Agnes Guerci, MD⁵^*, Hyacinthe Johnson Ansa⁶^*, Adlen Foudi, PhD²^*, Annelise Bennaceur-Griscelli, MD, PhD^7,8^* and Ali G Turhan, MD, PhD^9,10

¹Inserm U935, Villejuif, France
²Inserm U935 University Paris Sud, Villejuif, France
³Department of Hematology, Inserm U935 University Paris Sud, Villejuif, France
⁴Inserm U935, Université Paris Sud, Paris, France, Villejuif, France
⁵CHU de Nancy, Nancy, France
⁶CHU Caen, Department of Hematology, Caen, France
⁷Inserm U935, Department of Hematology- University Paris Sud, Villejuif, France
⁸Service Hématologie, Hopital Paul Brousse, Villejuif, France
⁹Faculty of Medicine University Paris Sud, Villejuif, France
¹⁰Department of Hematology, Inserm U935; Paris Sud University Hospitals Bicetre & Paul Brousse, Le Kremlin Bicetre, France

4014

Inflammatory Cytokine-Responsive ADAR1 Impairs Let-7 Biogenesis and Promotes Leukemia Stem Cell Generation

Maria Anna Zipeto, Ph.D¹^*, Angela Court Recart²^*, Nathaniel Delos Santos³^*, Qingfei Jiang, PhD⁴^*, Leslie A Crews, PhD³^* and Catriona HM Jamieson, MD, PhD³

¹Sanford Consortium for Regenerative Medicine, University of California San Diego, La Jolla, CA
²University of California San Diego, LA JOLLA, CA
³Division of Regenerative Medicine, University of California, San Diego, La Jolla, CA
⁴University of California San Diego, La Jolla, CA

4015

Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression

Valentín García-Gutierrez¹^*, Beatriz Colom-Fernandez²^*, Anna Kreutzman, PhD³, Luis Felipe Casado⁴^*, Fermín Sánchez-Guijo, MD⁵^*, Rosa M. Ayala, MD, PhD⁶, Concepcion Boque, PhD⁷^*, Blanca Xicoy, MD, PhD⁸^*, Isabel Montero, MD⁹^*, Cesar Soto¹⁰^*, Raquel De Paz¹¹^*, Joaquin Martinez Lopez, MD PhD⁶^*, Cecilia Muñoz-Calleja¹²^* and Juan Luis Steegmann, MD¹³

¹Hematology Department, Hospital Ramón y Cajal, Madrid, Spain
²Instituto de Investigación Sanitaria Princesa (IIS-IP). Servicio de Inmunología. Hospital Universitario de la Princesa, Madrid, Spain, Madrid, Spain
³Instituto de Invetigación Sanitaria Princesa. Servicio de Inmunología. Hospital Universitario de la Princesa., Madrid, Spain
⁴Servicio de Hematologíay Hematoterapia, Hospital Virgen de la Salud, Toledo., Toledo, Spain
⁵Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain
⁶Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
⁷Insitute Cotele d'Oncologie, Barcelona, Spain
⁸Hematology Service, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain
⁹Servicio de Hematología, Hospital Universitario Virgen del Rocío, Sevilla, Sevilla, Spain
¹⁰Servicio de Hematología, Hospital Povisa, Vigo, Vigo, Spain
¹¹Servicio de Hematología, Hospital Universitario de la Paz, Madrid, Madrid, Spain
¹²Instituto de Investigación Sanitaria Princesa (IIS-IP). Servicio de Inmunología. Hospital Universitario de la Princesa, Madrid, Spain
¹³Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Madrid, Spain

4016

Downregulation of Mir-181a Restores Chemosensitivity to Imatinib Mesylate in Chronic Myeloid Leukemia Cells Resistant to Tyrosine Kinase Inhibitors

Anna Chorzalska, PhD^1,2^*, Javier F Kim¹^*, Karim Roder, PhD^2,3^*, Adam J Olszewski, MD⁴, Dmitry Terentyev, PhD^2,3^* and Patrycja M Dubielecka, PhD^1,2^*

¹Signal Transduction Lab, Alpert Medical School of Brown University, Providence, RI
²Rhode Island Hospital, Providence, RI
³Department of Medicine, Alpert Medical School of Brown University, Providence, RI
⁴Division of Hematology-Oncology, Alpert Medical School of Brown University, Providence, RI

4017

A Bio-Integrative Approach Identifies an Inflammatory Signature in Chronic Myeloid Leukemia (CML) Stem Cells That Is Highly Perturbed in CML Blast Crisis and Involves REL transcription Factor

Christophe Desterke, PhD¹^*, Ludovic Marie-Sainte²^*, Amine Sbitti, PhD²^*, Ali Naama²^*, Annelise Bennaceur-Griscelli, MD, PhD^3,4,5, Ali G Turhan, MD, PhD^3,5,6 and Ivan Sloma, PharmD, PhD^7,8,9^*

¹SFR89, Paris-Sud University, Villejuif, France
²GEVITEAM, Maisons-Alforts, France
³Department of Hematology, Inserm U935; Paris Sud University Hospitals Bicetre & Paul Brousse, Le Kremlin Bicetre, France
⁴University paris Sud, Villejuif, France
⁵Service Hématologie, Hôpital Paul Brousse, Villejuif, France
⁶Faculty of Medicine University Paris Sud, Villejuif, France
⁷Faculté de Médecine, Université Paris-Sud, Le Kremelin Bicêtre, France
⁸Department of Hematology, Inserm U935 University Paris Sud, Villejuif, France
⁹Hôpital Paul Brousse, Service d'Hématologie, Assistance Publique des Hôpitaux de Paris, Villejuif, France

4018

Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients

Cesarina Giallongo¹^*, Nunziatina L Parrinello¹^*, Daniele Tibullo, Ph.D¹^*, Claudia Bellofiore¹^*, Piera La Cava¹^*, Alessandra Romano, MD, PhD¹^*, Annalisa Chiarenza²^*, Fabio Stagno, MD, PhD¹, Paolo Vigneri, MD/PhD³^*, Giuseppe A. Palumbo, MD⁴^* and Francesco Di Raimondo, MD/PhD⁵

¹Division of Haematology, AOU, Catania, Italy
²Division of Hematology, Ferrarotto Hospital, Catania, Italy
³Dep. Clinical and Experimental Medicine, University of Catania Medical School, Catania, Italy
⁴Division of Hematology, Ospedale Ferrarotto, University of Catania, Catania, Italy
⁵Section of Hematology, A.O.U. Policlinico "Vittorio Emanuele", Catania, Italy

4019

The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells

Chengwu Zeng^1,2^*, Sichu Liu²^*, Lijian Yang²^*, Shaohua Chen²^* and Yangqiu Li^1,2,3

¹First Affiliated Hospital, Jinan University, Guangzhou, China
²Institute of Hematology, Medical College, Jinan University, Guangzhou, China
³Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China

4020

Inecalcitol, a Novel Adjuvant Therapy Inhibiting Chronic Myeloid Leukemia (CML) Stem Cells, Activates a Macrophage Differentiation Pathway in Leukemic Progenitors

Christophe Desterke, PhD¹^*, Hyacinthe Johnson-Ansa, MD²^*, Patricia Hugues³^*, Jean Francois Dufour-Lamartinie, MD⁴^*, Remi Delansorne, PhD⁴^*, Agnes Guerci, MD⁵^*, Annelise BENNACEUR Griscelli, MD, PhD⁶^* and Ali G Turhan, MD, PhD⁷

¹Paris 11 University, Inserm UMR972, Villejuif, France
²CHU Caen, Department of Hematology, Caen, France
³Inserm U935 University Paris Sud, Villejuif, France
⁴Hybrigenics, Paris, France
⁵CHU de Nancy, Nancy, France
⁶Inserm U935, Department of Hematology, Villejuif, France
⁷Department of Hematology, Inserm U935; Paris Sud University Hospitals Bicetre & Paul Brousse, Le Kremlin Bicetre, France

See more of: Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH